Cambridge, MA, United States

Time filter

Source Type

Patent
Constellation Pharmaceuticals | Date: 2016-09-27

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.


Patent
Constellation Pharmaceuticals | Date: 2016-09-06

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.


Patent
Constellation Pharmaceuticals | Date: 2015-04-02

Described herein are novel methods for treating subjects with a cancer which is not overexpressing at least one of BCL-xL, BCL-w, and BAD, and optionally further overexpressing BCL-2. Also provided herein are tools for determining and/or assessing, and for the administration of, cancer treatments involving BET bromodomain inhibitors, BCL-xL inhibitors, or combinations thereof.


Patent
Constellation Pharmaceuticals | Date: 2017-02-08

Described herein are novel methods for treating subjects with a cancer which is not overexpressing at least one of BCL-xL, BCL-w, and BAD, and optionally further overexpressing BCL-2. Also provided herein are tools for determining and/or assessing, and for the administration of, cancer treatments involving BET bromodomain inhibitors, BCL-xL inhibitors, or combinations thereof.


The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1- methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.


The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2015-11-25

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R^(1)-R^(4 )of formula (I) and R^(1)-R^(3 )of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2016-04-11

The present invention relates to use of CBP/EP300 bromodomain inhibitors for the treatment of cancer.


Patent
Constellation Pharmaceuticals | Date: 2015-05-08

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.


Patent
Constellation Pharmaceuticals | Date: 2016-05-16

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

Loading Constellation Pharmaceuticals collaborators
Loading Constellation Pharmaceuticals collaborators